Does Medicare Cover CBD Gummies? The 2026 Program Explained

Does Medicare Cover CBD Gummies? (Yes, Starting April 2026)

If your doctor's practice belongs to a specific kind of Medicare provider organization, and that organization opted into the Substance Access BEI, then yes. As of April 1, 2026, qualifying Medicare patients can receive up to $500 a year in hemp-derived CBD gummies, oils, tinctures, and capsules at no out-of-pocket cost.

If your doctor's practice didn't opt in, the answer is no. In that case, you'll buy CBD the way most people still do: direct from a hemp farm.

This post walks through what the new Medicare CBD program covers, who qualifies, how the $500 benefit works, and what happens if your provider isn't participating yet. We'll also cover what's happening in Washington this month, where the Trump administration is pressing Congress to expand and protect hemp access before a separate hemp law takes effect in November.

For the broader reference page, see our complete Medicare CBD guide. This post focuses on the 2026 program update specifically.

What Is the New Medicare CBD Pilot Program?

The program goes by an awkward name: the Substance Access Beneficiary Engagement Incentive, or BEI. CMS announced it in 2025, finalized the implementation rules earlier this year, and turned it on April 1, 2026.

It runs as a pilot inside the CMS Innovation Center. There's no permanent statute behind it yet. The agency is collecting outcome and cost data over the pilot period, after which Congress would need to act to make the benefit permanent.

The Substance Access BEI: How CMS Structured It

A Beneficiary Engagement Incentive is a tool CMS already uses in other Innovation Center programs. It lets a participating provider organization offer something of value to a patient as part of a clinical care plan, without that something counting as an illegal kickback under federal anti-kickback rules.

Under the Substance Access BEI, the "something of value" is hemp-derived CBD product up to $500 per beneficiary per year, distributed through the patient's care team rather than a pharmacy.

Two things make this structurally different from how Medicare normally pays for things. First, there's no Medicare claim and no Part D run. The provider organization buys the products and gives them to the patient inside the care plan. Second, CMS doesn't reimburse the provider for the cost. The provider funds the BEI from its own budget, betting that better adherence and fewer hospitalizations will pay back through the model's shared-savings math at year-end.

Which Medicare Models Are Participating

Three CMS Innovation Center models are in scope.

• ACO REACH Model. Five participating ACOs submitted Substance Access BEI implementation plans for the current performance period. CMS is reviewing them.
• Enhancing Oncology Model. Available to oncology practices in this model that elect the BEI.
• Long-Term Enhanced ACO Design (LEAD) Model. Joins in 2027.

If your doctor isn't part of an ACO REACH organization, an Enhancing Oncology Model practice, or eventually a LEAD ACO, the program isn't open to you yet. That covers most Medicare beneficiaries today. Adoption will widen as more providers run the math and elect in.

What CBD Products Does Medicare Cover?

The program is specific. Read the rule carefully before assuming the gummy in your cabinet qualifies.

Covered: Gummies, Oils, Tinctures, Capsules (Orally Administered Only)

The product has to be taken by mouth. That means CBD gummies you chew, oils or tinctures held under the tongue, capsules swallowed with water, and similar oral solutions. The mechanism of administration is the gating rule.

Our reference page on which CBD products qualify for Medicare goes deeper on the specifics. The short version: oral CBD is in.

Not Covered: Smokable, Inhalable, or Topical CBD

Anything you smoke, vape, or inhale is excluded. So is anything you rub on your skin. CBD flower, pre-rolls, cartridges, vape pens, balms, salves, and patches are out. The CMS rule is firm. There's no workaround.

This isn't a comment on whether those products work for what people use them for. It's the program design choice CMS made when writing the BEI rules. If a provider tries to dispense an excluded format under the BEI, they're out of compliance with their own implementation plan.

The Federal Product Requirements (THC Limits + Third-Party Testing)

To qualify under the BEI, a product has to be:

• Hemp-derived. Cannabinoids must come from cannabis sativa grown under the 2018 Farm Bill, not synthetic.
• Under 0.3% Delta-9 THC by dry weight. This is the federal hemp definition. Every product on our farm meets it. That's how we ship interstate.
• Under 3 mg total THC per serving. Total THC, not just Delta-9. This is stricter than the dry-weight rule and rules out high-dose hemp Delta-9 gummies.
• Third-party lab tested. A current Certificate of Analysis from an independent lab, showing cannabinoid content and contaminant screening.

Third-party testing is the requirement most consumer brands fail quietly. Our COAs live on the public Third-Party Labs page at wholesalehempfarms.com/pages/hemp-flower-labs. If a product doesn't have a COA you can read, the provider can't legally dispense it under the BEI.

Who Qualifies for the Medicare CBD Benefit?

Three conditions, and all three have to be true at the same time.

The 3 Conditions Every Patient Must Meet

1. You're enrolled in Medicare. Original Medicare or Medicare Advantage both work. The BEI sits inside the Innovation Center model, not inside any specific Part. 2. Your doctor's practice belongs to a participating organization. That's the ACO REACH, Enhancing Oncology, or (in 2027) LEAD ACO test. The org has to have elected the BEI and submitted a CMS-approved implementation plan. 3. You meet the clinical criteria the provider set in their plan. Each participating organization writes its own clinical guidance: which conditions, which patient profiles, how the product is dispensed. Two ACOs can have different criteria and both be in compliance.

There are also baseline rules: 18 or older, not pregnant or nursing, and clinically appropriate per the provider's judgment.

For a fuller walkthrough of who qualifies for the Medicare CBD benefit, see our reference page.

How to Check If Your Doctor's Practice Participates

Two ways. Easier first: ask. The next time you're at your primary-care or oncology office, ask whether the practice is part of an ACO REACH organization or an Enhancing Oncology Model and whether they've elected the Substance Access BEI. The front-desk staff usually won't know. The practice manager or the medical director will.

Harder, but doable cold: pull the public CMS list of ACO REACH and EOM participants from the Innovation Center site and search for your practice's parent organization.

If you're already enrolled in a participating ACO, your care team is supposed to discuss it with you when it's clinically relevant. That's the design.

How Much Does Medicare Pay? The $500/Year Benefit Explained

Up to $500 per beneficiary per year, in hemp-derived CBD product value, distributed by the provider organization within the care plan.

Who Actually Pays (The Provider, Not Government Directly)

CMS isn't cutting checks for CBD. The participating provider organization (the ACO or oncology practice) absorbs the product cost on its own books. CMS lets them do it without it counting as an illegal kickback. The bet for the provider is downstream: if BEI patients have fewer ER visits, fewer hospitalizations, or better adherence to other parts of their care plan, the model's shared-savings calculation pays the org back at year-end.

That's why adoption will be uneven. A well-funded ACO running the model with confidence may elect the BEI quickly. A smaller practice may wait for early results before committing budget.

What Patients Owe Out of Pocket ($0 for Qualifying Patients)

For a patient who qualifies and whose provider has elected the BEI: zero. No copay, no deductible application, no Medicare claim. The provider hands over the product as part of the care plan.

If you're outside the qualifying group, the program doesn't offset your purchase. You pay retail or, if you know where to look, farm-direct.

For the step-by-step, see how the Medicare CBD program works step by step.

Do Wholesale Hemp Farms CBD Gummies Qualify for the Program?

We've been farming hemp in Wilmore, Kentucky since 2018. Our farm is USDA Organic certified. Our gummies are oral, our hemp is Farm Bill compliant at under 0.3% Delta-9 THC by dry weight, and every batch goes to a third-party lab before it ships. Public COAs sit on our site for anyone (including a participating ACO's compliance officer) to verify.

Two of our oral CBD products fit the BEI's product profile cleanly: the CBD Pain Recovery and Wellness Hemp Gummy and the CBD Sleep Support Hemp Gummy. Both are CBD-focused, hemp-derived, third-party tested, and orally administered.

What we don't do is the part that disqualifies most brands: synthetics, conversion chemistry, hidden testing. Our COAs name the lab, the date, and the full cannabinoid breakdown. If a provider's compliance team wants to verify the exact total-THC-per-serving number on a specific product before approving it for their BEI program, they read the current COA the same as anyone else.

The other piece is farm provenance. The BEI rules don't require USDA Organic, but a participating org's compliance team is going to want a clean supply chain. Our our USDA Organic CBD gummies come from a single licensed Kentucky farm with a live camera on the field. That's not a marketing claim. It's a federal certification audit and a publicly streamed video feed.

If your doctor's practice has elected the BEI and is looking for a qualifying supplier, our team will provide whatever documentation their compliance officer asks for. Real farmers on this end.

What's Next: Trump and Congress Push for Medicare CBD Expansion (April 2026)

Two parallel things are happening in Washington this month.

The Substance Access BEI itself survived its first court test. A coalition of nine drug-policy groups led by Smart Approaches to Marijuana sued in late March, asking the federal court in D.C. to block the program. The court denied their emergency request on April 1, the same day the program went live. The lawsuit is still pending on the merits, but the program is operating.

On April 27, 2026, the House Rules Committee took up legislative amendments tied to the broader hemp law. The Trump administration is publicly pressing Congress to amend Section 781 of the underlying hemp law, which would cap total THC at 0.4 milligrams per container starting November 13, 2026. Left in place, the Section 781 cap would reshape much of the hemp industry. The administration's position, repeated this week, is that Congress should fix the cap while keeping the broader compliance frame intact.

The two stories are linked. A working Medicare CBD pilot needs a viable hemp supply to draw from. If Section 781 takes effect unchanged, the supply side narrows considerably right when the demand side is opening up. We're watching the committee schedule the same way the rest of the industry is.

We'll update our Medicare CBD pages as the rules change. The product side of our farm doesn't change with the politics. We grow the same way in 2026 we did in 2018: USDA Organic, on our own land, third-party tested, farm-direct.